Abstract:Objective: This study aimed to evaluate the effectiveness and safety of Allisartan Isoproxil in the management of hypertension. Methods: A comprehensive search was conducted across both English and Chinese databases, including the Cochrane Library, Embase, PubMed, Web of Science, Chinese Journal Full Text Database (CNKI), Wanfang Digital Periodical Full Text Database, and VIP Chinese Periodical Database (VIP), up to March 24, 2024. Randomized controlled trials (RCTs) investigating alisartan axetil for hypertension management were selected. Literature quality was assessed, and data were extracted for meta-analysis using Stata 15.1 software. The quality of evidence for outcome indicators was evaluated using the GRADE system level. Results: Six RCTs involving 767 participants were included. Meta-analysis revealed that, compared to placebo, the Allisartan Isoproxil group exhibited a significant reduction in systolic blood pressure (SBP) [WMD = −8.08, 95% CI (−11.81, 4.10), p = 0.000] and brachial-ankle pulse wave velocity (baPWV) [SMD = −0.69, 95% CI (−1.17, 0.20), p = 0.006]. However, the reduction in diastolic blood pressure (DBP) was not statistically significant [WMD = −5.48, 95% CI (−11.07, 0.10), p = 0.054]. Additionally, compared to calcium channel blockers (CCB) and angiotensin II receptor blockers (ARB), Allisartan Isoproxil did not significantly affect SBP [WMD = 0.20, 95% CI (−3.71, 4.10), p = 0.921] or DBP [WMD = 0.16, 95% CI (−2.11, 2.43), p = 0.891]. Allisartan Isoproxil demonstrated superior effects in increasing nitric oxide (NO) levels and decreasing endothelin (ET) levels compared to control groups [WMD = 9.56, 95% CI (6.42, 12.71), p = 0.000], [WMD = −7.42, 95% CI (−11.13, −3.71), p = 0.000], and showed a higher effective control rate of blood pressure [RR = 1.26, 95% CI (1.13, 1.41), p = 0.000]. Subgroup analysis did not reveal significant differences. Regarding safety, there were no statistically significant differences in adverse events between the Allisartan Isoproxil group and the control groups [RR = 0.99, 95% CI (0.74, 1.32), p = 0.928], and no fatal adverse events were reported. Conclusion: Allisartan Isoproxil is effective in reducing SBP and baPWV, increasing NO, decreasing ET, and achieving a higher control rate of blood pressure in patients with essential hypertension. These benefits are achieved with minimal adverse reactions. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023467869, identifier PROSPERO CRD42023467869.

Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.

Effects and Safety of Allisartan Isoproxil Combined with Amlodipine or Indapamide in Patients with Hypertension Who Failed Allisartan Monotherapy

Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis

Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial

Efficacy Comparison Between 5 Mg Perindopril Arginine Salt and 4 Mg Perindopril Tert-Butylamine Salt for Patients with Mild to Moderate Essential Hypertension

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

PS 17-77 A RANDOMIZED, DOUBLE-BLIND AND DOUBLE-DUMMY, MULTIPLE-DOSE, POSITIVE AND PARALLEL COMPARATIVE, MULTICENTER CLINICAL TRIAL OF ALLISARTAN EVALUATE EFFICACY AND SAFETY IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension

Effects of Telmisartan on Mild to Moderate Essential Hypertension Assessed by 48 H Ambulatory Blood Pressure Monitoring

Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage

Effect of Domestic Produced Bisoprolol Fumarate/Hydrochlorothiazide in Patients with Mild to Moderate Essential Hypertension

Effect of telmisartan on microalbuminuria in patients with hypertension

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

A Comparison of Initial Treatment with Losartan/hctz Versus Losartan Monotherapy in Chinese Patients with Mild to Moderate Essential Hypertension.

Influence of valsartan on Microalbuminuria of Essential Hypertensive Patients

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

Efficacy of Losartan versus Enalapril in Treatment of Mild and Moderate Hypertension

Amlodipine/valsartan 5/160mg Versus Valsartan 160mg in Chinese Hypertensives

The Effectiveness and Safety of L-amlodipine Besylate for Blood Pressure Control in Patients with Mild to Moderate Essential Hypertension